Seres Therapeutics Return on Equity

Seres Therapeutics (MCRB) currently reports a ROE of -65.05%. That is below the Healthcare sector average of 20.86%. Use the charts on this page to explore Seres Therapeutics's ROE history and peer comparisons.

Seres Therapeutics's ROE of -65.05% is lower than the Healthcare sector average of 20.86%. That is roughly 411.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Seres Therapeutics's current -65.05% should be judged against Healthcare norms (sector average: 20.86%) and against MCRB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -65.05%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Seres Therapeutics, and consider following MCRB for alerts when major investors trade the stock.

Seres Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -65.05% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MCRB with unrelated industries.